Comparison of different anticoagulation strategies for renal replacement therapy in critically ill patients with COVID-19: a cohort study
Authors:
Open Access
- 16 November 2020
- journal article
- research article
- Published by Springer Nature in BMC Nephrology
- Vol. 21 (1) , 1-9
Abstract
Background: Critically ill coronavirus disease 2019 (COVID-19) patients have a high risk of acute kidney injury (AKI) that requires renal replacement therapy (RRT). A state of hypercoagulability reduces circuit life spans. To maintain circuit patency and therapeutic efficiency, an optimized anticoagulation strategy is needed. This study investigates whether alternative anticoagulation strategies for RRT during COVID-19 are superior to administration of unfractionated heparin (UFH). Methods: Retrospective cohort study on 71 critically ill COVID-19 patients (≥18 years), admitted to intensive care units at a tertiary health care facility in the southwestern part of Germany between February 26 and May 21, 2020. We collected data on the disease course, AKI, RRT, and thromboembolic events. Four different anticoagulatory regimens were administered. Anticoagulation during continuous veno-venous hemodialysis (CVVHD) was performed with UFH or citrate. Anticoagulation during sustained low-efficiency daily dialysis (SLEDD) was performed with UFH, argatroban, or low molecular weight heparin (LMWH). Primary outcome is the effect of the anticoagulation regimen on mean treatment times of RRT. Results: In patients receiving CVVHD, mean treatment time in the UFH group was 21.3 h (SEM: ±5.6 h), in the citrate group 45.6 h (SEM: ±2.7 h). Citrate anticoagulation significantly prolonged treatment times by 24.4 h (P = .001). In patients receiving SLEDD, mean treatment time with UFH was 8.1 h (SEM: ±1.3 h), with argatroban 8.0 h (SEM: ±0.9 h), and with LMWH 11.8 h (SEM: ±0.5 h). LMWH significantly prolonged treatment times by 3.7 h (P = .008) and 3.8 h (P = .002), respectively. Conclusions: UFH fails to prevent early clotting events in the dialysis circuit during COVID-19. For patients, who do not require effective systemic anticoagulation, regional citrate dialysis is the most effective strategy. For patients, who require effective systemic anticoagulation, the usage of LMWH results in the longest circuit life spans. The proposed anticoagulatory strategies are safe, can easily be monitored, and allow an individualized treatment. GraphicalKeywords
All Related Versions
Funding Information
- Else Kröner-Fresenius-Stiftung (2016_Kolleg.03, 2017_EKES.34)
- Deutsche Forschungsgemeinschaft (SFB 1160 (P06/ B08))
- Berta-Ottenstein-Programme for Clinician Scientists, Faculty of Medicine, University of Freiburg
- Berta-Ottenstein-Programme for Advanced Clinician Scientists, Faculty of Medicine, University of Freiburg
This publication has 32 references indexed in Scilit:
- Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a meta-analysis with trial sequential analysis of randomized controlled trialsCritical Care, 2016
- Fluid OverloadCritical Care Clinics, 2015
- A Randomized Controlled Trial of Regional Citrate Versus Regional Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Adults*Critical Care Medicine, 2015
- NoticeKidney International Supplements, 2013
- NoticeKidney International Supplements, 2012
- Parenteral AnticoagulantsChest, 2012
- Clinical review: Patency of the circuit in continuous renal replacement therapyCritical Care, 2007
- Filter Run Time in CVVH: Pre- versus Post-Dilution and Nadroparin versus Regional Heparin-Protamine AnticoagulationBlood Purification, 2005
- Anticoagulation for Continuous Renal Replacement Therapy2004
- Different patterns of heparin resistance: therapeutic implicationsPerfusion, 2002